Hedera Dx

1 in 3 people will be diagnosed with cancer in their lifetime (according to cancer.org). Therefore, it is critical to detect it when it matters most. Powerful new blood-based cancer detection technologies such as ctDNA are emerging into clinical use, easing the screening process.
Furthermore, the information gathered from these analyses will take our awareness of cancer to the next level unlocking new possibilities.
However, all of these new technologies add a lot of complexities to the daily clinical workflow, requiring new tools for easy access and usability.

Hedera platform solves that challenge, giving a streamlined experience for clinicians to access information and liquid biopsy tests in early detection, therapy selection and recurrence monitoring.


Hedera Dx
Alanine Building
Route de la Corniche 5
1066 Epalinges


  • Liquid biopsy
  • Software as a Service (SaaS)
  • Oncology
  • Prevention
  • Cancer